Summary
After administration of a single oral dose of benzbromarone 100 mg to 7 subjects, the maximum serum level was 1.84±0.87 mg/l, and the elimination halflife was 2.77±1.07 h. The major metabolite, benzarone, could be detected in serum 3 h after administration of benzbromarone, and the maximum serum benzarone level of 0.79±0.21 mg/l occurred after 6 h. Benzarone had an elimination half-life from serum of 13.52±2.18 h. Both substances were excreted mainly via the liver and bile. In urine only benzarone β-glucuronide could be detected; it amounted to 1.55% of the benzbromarone dose.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Zöllner N, Griebsch A, Fink JK (1970) On the effect of benzbromarone on serum uric acid levels and uric acid excretion in patients with gout. Dtsch Med Wochenschr 95: 2405–2412
Jain AK, Ryan JR, McMahon FG, Novek RJ (1974) Effect of single oral doses of benzbromarone on Serum and Urinary uric acid. Arthritis Rheum 17: 149
Kramp R, Lenoix R (1975) Distal permeability of urate and effects of benzofuran derivatives in the rat kidney. Am J Physiol 228: 875–883
Delbarre F, Auscher C, Oliver J, Rose A (1967) Traitement des hyperuricemics et de lagoutte par des clerives du benzofuranne. Sem Hop Paris 43: 1127–1133
Yu T (1976) Pharmacokinetics and clinical studies of a new uricosuric agent-benzbromarone. J Rheumatol 3: 305–312
Broekhuysen J, Pacco R, Sion L, Demeulenaese M, van Hel (1972) Metabolism of benzbromarone in man. Eur J Clin Pharmacol 4: 125–130
Rothe W, Schellhorn J (1977) Vorschlag einer Arzneibuchmethode zur Prüfung der Auflösungsrate von Wirkstoffen. Pharm Ind 39: 801–806
Vergin H, Bishop GB (1980) High-performance liquid chromatography determination of benzbromarone and its major metabolite benzarone in Serum. Chromatogr Biomed Appl 183: 383–386
Diamond HS (1978) Uricosuric drugs. In: Handbook of experimental pharmacology, Vol. 51, Chap 20. Springer, Berlin Heidelberg New York, pp 459–484
Broekhuysen J, Bekaert J, Rozenblum C, Deltour G (1965) Arch Int Pharmacodyn Ther 158: 165
Heel RC, Brodgen RN, Speight TM, Avery GS (1977) Benzbromarone: A review of its pharmacological properties and therapeutic use in gout and hyperurikaemia. Drugs 14: 349–366
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ferber, H., Vergin, H. & Hitzenberger, G. Pharmacokinetics and biotransformation of benzbromarone in man. Eur J Clin Pharmacol 19, 431–435 (1981). https://doi.org/10.1007/BF00548587
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00548587